100 filings
Page 3 of 5
6-K
ip98pny6tt
6 Mar 23
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
6:02am
6-K
xf5wc5d quh
23 Feb 23
Current report (foreign)
6:03am
6-K
6v2 71ktzq
13 Feb 23
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
6:03am
6-K
gnbzblccvs5uv
6 Feb 23
Opthea To Present at SVB Leerink Global Biopharma Conference
6:02am
6-K
8e84fs06apl7k65pyq
30 Jan 23
Opthea To Present at Sequire Biotechnology Conference
6:02am
6-K
4yrq2hk i00v7gxe6
11 Jan 23
Current report (foreign)
6:02am
6-K
axsgj7bv iwr0
12 Dec 22
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
6:04am
6-K
elh3tjkvxgpka7xdya
6 Dec 22
Current report (foreign)
6:02am
6-K
8v0tf4w m3alng8s4b2
16 Nov 22
Current report (foreign)
4:18pm
6-K
cl52v3ae 74r
10 Nov 22
Opthea to Present at Jefferies London Healthcare Conference
4:17pm
6-K
mzco1qj 1ernq
24 Oct 22
Current report (foreign)
6:01am
6-K
57ia8yutes5oqix5t8t
26 Sep 22
Market Announcements Office
4:15pm
6-K
rulz0e1d
30 Aug 22
Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
7:02am
6-K
w978mzfr41xl6 3lcri
26 Aug 22
Notice of Extraordinary General Meeting and Explanatory Notes
4:31pm
6-K
wvm qh1onm
25 Aug 22
Current report (foreign)
4:30pm
6-K
l539 kdbaw08kp
15 Aug 22
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
6:08am
6-K
m40 qli9kkp
11 May 22
Opthea To Present at Upcoming Investor Conferences
6:03am
6-K
av2plfy5p
10 May 22
Current report (foreign)
6:02am
6-K
blpxec9pdo uyk
5 May 22
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022
6:02am
6-K
50yhwalm
29 Apr 22
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting
6:03am